These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26242693)

  • 21. Antibodies against light neurofilaments in multiple sclerosis patients.
    Bartos A; Fialová L; Soukupová J; Kukal J; Malbohan I; Pitha J
    Acta Neurol Scand; 2007 Aug; 116(2):100-7. PubMed ID: 17661795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mice with disrupted midsized and heavy neurofilament genes lack axonal neurofilaments but have unaltered numbers of axonal microtubules.
    Elder GA; Friedrich VL; Pereira D; Tu PH; Zhang B; Lee VM; Lazzarini RA
    J Neurosci Res; 1999 Jul; 57(1):23-32. PubMed ID: 10397632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma neurofilament light in progressive multiple sclerosis.
    Zetterberg H
    Acta Neurol Scand; 2020 Jan; 141(1):14-15. PubMed ID: 31618445
    [No Abstract]   [Full Text] [Related]  

  • 24. Intermediate filaments: a common thread in neuromuscular disorders.
    Herrmann DN; Griffin JW
    Neurology; 2002 Apr; 58(8):1141-3. PubMed ID: 11971077
    [No Abstract]   [Full Text] [Related]  

  • 25. Expression of neurofilament proteins in developing neurons.
    Schilling K; Pilgrim C
    Acta Histochem Suppl; 1990; 38():77-80. PubMed ID: 2127855
    [No Abstract]   [Full Text] [Related]  

  • 26. CSF neurofilament light: A universal risk biomarker in multiple sclerosis?
    Khalil M; Salzer J
    Neurology; 2016 Sep; 87(11):1068-9. PubMed ID: 27521432
    [No Abstract]   [Full Text] [Related]  

  • 27. Neurofilament light chain: An important step toward a disease biomarker in multiple sclerosis.
    Berger T; Stüve O
    Neurology; 2019 Mar; 92(10):451-452. PubMed ID: 30737335
    [No Abstract]   [Full Text] [Related]  

  • 28. Neurofilament light in blood - What more is needed for clinical implementation in multiple sclerosis?
    Zetterberg H
    EBioMedicine; 2020 Jul; 57():102826. PubMed ID: 32574951
    [No Abstract]   [Full Text] [Related]  

  • 29. Serum neurofilament light and prediction of multiple sclerosis in clinically isolated syndrome.
    Zetterberg H; Svenningsson A
    Neurology; 2019 Feb; 92(7):313-314. PubMed ID: 30635493
    [No Abstract]   [Full Text] [Related]  

  • 30. [Multiple sclerosis: current diagnostic and therapeutic data].
    Schoenen J; Burton L; Figiel C; Delwaide PJ
    Rev Med Liege; 1979 Mar; 34(5):145-53. PubMed ID: 219459
    [No Abstract]   [Full Text] [Related]  

  • 31. After the storm: neurofilament levels as a surrogate endpoint for neuroaxonal damage.
    Giovannoni G; Nath A
    Neurology; 2011 Apr; 76(14):1200-1. PubMed ID: 21346219
    [No Abstract]   [Full Text] [Related]  

  • 32. Combined Neurofilament Light and Optical Coherence Tomography Better Predicts Multiple Sclerosis Disease Activity Than Either Measure Alone.
    Krämer J; Wiendl H; Meuth SG; Albrecht P
    Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34348970
    [No Abstract]   [Full Text] [Related]  

  • 33. Extending the clinicopathological spectrum of neurofilament inclusion disease.
    Josephs KA; Uchikado H; McComb RD; Bashir R; Wszolek Z; Swanson J; Matsumoto J; Shaw G; Dickson DW
    Acta Neuropathol; 2005 Apr; 109(4):427-32. PubMed ID: 15754170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurofilament phosphorylation and their proline-directed kinases in health and disease.
    Holmgren A; Bouhy D; Timmerman V
    J Peripher Nerv Syst; 2012 Dec; 17(4):365-76. PubMed ID: 23279337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurofilament subunits can undergo axonal transport without incorporation into Triton-insoluble structures.
    Jung C; Yabe J; Wang FS; Shea TB
    Cell Motil Cytoskeleton; 1998; 40(1):44-58. PubMed ID: 9605971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Composite bottlebrush mechanics: α-internexin fine-tunes neurofilament network properties.
    Kornreich M; Malka-Gibor E; Laser-Azogui A; Doron O; Herrmann H; Beck R
    Soft Matter; 2015 Aug; 11(29):5839-49. PubMed ID: 26100609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diagnostic value of cerebrospinal fluid study in multiple sclerosis].
    Schädlich HJ
    Fortschr Neurol Psychiatr; 1990 Jul; 58(7):247-51. PubMed ID: 2202622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss.
    Petzold A
    J Neurol Sci; 2005 Jun; 233(1-2):183-98. PubMed ID: 15896809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tracking therapies in MS: More evidence in favor of neurofilament.
    Yeh EA; Sormani MP
    Neurology; 2020 Mar; 94(11):465-466. PubMed ID: 32047072
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.